Detalhe da pesquisa
1.
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
N Engl J Med
; 388(18): 1645-1656, 2023 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37133584
2.
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
N Engl J Med
; 387(1): 9-20, 2022 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35665782
3.
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 566(7745): E11-E12, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30755741
4.
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
Lancet Oncol
; 25(6): 707-719, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38710187
5.
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 554(7691): 189-194, 2018 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29420467
6.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
N Engl J Med
; 382(7): 610-621, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31825192
7.
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.
J Natl Compr Canc Netw
; 21(1): 33-41.e16, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36634607
8.
SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA.
Future Oncol
; 2022 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36200668
9.
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial.
Oncologist
; 26(8): e1327-e1338, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34028126
10.
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.
Breast Cancer Res Treat
; 189(2): 377-386, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34264439
11.
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens.
Breast Cancer Res Treat
; 188(2): 449-458, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33909203
12.
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
Lancet Oncol
; 21(10): 1283-1295, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33002436
13.
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Lancet Oncol
; 21(11): 1455-1464, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33152285
14.
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 21(1): 33-43, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31838010
15.
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
Breast Cancer Res
; 22(1): 115, 2020 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33109233
16.
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Breast Cancer Res
; 22(1): 120, 2020 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33138866
17.
Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
Breast Cancer Res Treat
; 184(2): 469-479, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32876911
18.
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Lancet Oncol
; 20(8): 1124-1135, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31257177
19.
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 20(9): 1226-1238, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31402321
20.
Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement.
Oncologist
; 24(5): 603-611, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30710068